Introduction Numerous diagnostic criteria have tried to tackle the variability in clinical manifestations and problematic diagnosis of vascular cognitive impairment (VCI) but none have been universally accepted. These criteria have not been readily comparable, impacting on clinical diagnosis rates and in turn prevalence estimates, research, and treatment. Methods The Vascular Impairment of Cognition Classification Consensus Study (VICCCS) involved participants (81% academic researchers) from 27 countries in an online Delphi consensus study. Participants reviewed previously proposed concepts to develop new guidelines. Results VICCCS had a mean of 122 (98–153) respondents across the study and a 67% threshold to represent consensus. VICCCS redefined VCI including classification of mild and major forms of VCI and subtypes. It proposes new standardized VCI-associated terminology and future research priorities to address gaps in current knowledge. Discussion VICCCS proposes a consensus-based updated conceptualization of VCI intended to facilitate standardization in research.
Bibliographical noteFunding Information:
This work was supported by a project grant (Ref117) from the Alzheimer's Society (UK).
Declaration of interests: Prof. Ford reports personal fees from Pfizer, Athersys, AstraZeneca, Lundbeck, Cerevast, and Daiichi Sankyo and grants and personal fees from Boehringer Ingelheim, outside the submitted work. Prof. O'Brien reports personal fees from GE Healthcare, TauRx, and Cytox and grants and personal fees from Avid/Lilly, outside the submitted work. Prof. Skoog reports personal fees and other from Takeda, outside the submitted work. Outside the submitted work, Prof. Black reports institutional grants from Pfizer, GE Healthcare, Eli Lilly, Elan/Transition Therapeutics, Roche, and Cognoptix and personal fees from Pfizer, GE Healthcare, Eli Lilly, Eisai, Boehringer Ingelheim, and Novartis.
- Vascular cognitive impairment
- Vascular dementia